Tafluprost is well tolerated in OHT eyes

Article

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT).

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT), reveals an investigation in the British Journal of Ophthalmology.

Dr Elena Milla and her team, Glaucoma and Genetics Unit, Institut Comtal d'Oftalmologia, Barcelona, Spain, conducted a prospective non-interventional, multicentre, observational study on 134 patients. Follow-ups were completed at baseline and one and three months post-treatment.

Five ocular surface symptoms were evaluated as absent, mild, moderate and severe. Tear break-up time, keratitis, conjunctival hyperaemia, blepharitis, Schirmer test and tear meniscus were all assessed in each patient.

A significant improvement in all symptoms was seen in 53% of patients with OHT. This included stinging/burning/irritation, itching, foreign body sensation, tearing and dryness sensation three months after treatment.

All signs except the Schirmer test results improved in the OHT patients. In the glaucomatous eyes the keratitis, hyperaemia and tear meniscus improved at one and three months post-treatment.

Preservative-free tafluprost is a well-tolerated hypotensive agent that can be used to treat naïve eyes and eyes with ocular surface problems.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.